Jan Stahlberg
Known title: 10% OwnerCIK: 0001983161
Jan Stahlberg's purchase track record
How the stock did after each of Jan Stahlberg's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since June 28, 2024
Stock higher 6 months later
67%
3 months: 83%
Median 6-month return
+40.8%
3 months: +26.0%
Beat the S&P 500
67%
median +33.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/25/2025 | DMAC | $627K | -5.3% | -30.0% | +11.1% |
| 11/17/2025 | DMAC | $7.00M | +35.7% | -11.4% | +10.9% |
| 8/21/2025 | DMAC | $3.34M | +21.8% | +43.3% | +7.7% |
| 8/13/2025 | DMAC | $2.62M | +5.2% | +38.3% | +7.3% |
| 7/23/2025 | DMAC | $5.40M | +30.3% | +54.8% | +8.1% |
| 6/28/2024 | DMAC | $3.00M | +41.7% | +83.4% | +9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMAC | ▲ Buy | Open Market | 73,099 | $627K | 11/25/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 40,253 | $318K | 11/24/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 208,872 | $1.5M | 11/21/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 128,426 | $951K | 11/20/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 240,352 | $1.7M | 11/19/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 182,882 | $1.2M | 11/18/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 187,393 | $1.2M | 11/17/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 50,772 | $305K | 8/27/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 59,648 | $358K | 8/26/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 338,265 | $2.0M | 8/25/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 59,788 | $357K | 8/22/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 48,172 | $287K | 8/21/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 71,107 | $416K | 8/20/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 8,233 | $49K | 8/15/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 70,414 | $422K | 8/14/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 293,601 | $1.7M | 8/13/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 1,542,857 | $5.4M | 7/23/2025 | View on chart |
| DMAC | ▲ Buy | Open Market | 1,200,000 | $3.0M | 6/28/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.